To further validate the SFKs and INSR/IGF-1R combined inhibition as a putative treatment strategy, blasts obtained from the four different T-ALL PDXs were treated with either dasatinib, BMS-754807 or the combination of both drugs ex vivo using a 10-by-10 drug combination matrix as illustrated in Fig. 6a. Here, IGF1R is linked to acute lymphoblastic leukemia.